As expected, compared to that of GL-261 WT tumor-bearing mouse CD8 + T cells, the antitumor immunity of GL-261 LGALS9−/− tumor-bearing mouse CD8 + T cells was enhanced, with an increased proportion of Ki67-positive cells and enhanced expression of IFN-γ/GzmB (Fig. 6j–l). This evidence concerns the gene LGALS9 and neoplasm.